CA2969456A1 - Methods and compositions for adoptive cell therapy - Google Patents

Methods and compositions for adoptive cell therapy Download PDF

Info

Publication number: CA2969456A1
Authority: CA; Canada
Prior art keywords: car; domain; cells; subject; receptor
Prior art date: 2014-12-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA2969456A

Other languages

English (en)

French (fr)

Inventor

Mark J. Gilbert

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Juno Therapeutics Inc

Original Assignee

Juno Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-03

Filing date

2015-12-03

Publication date

2016-06-09

2015-12-03 Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc

2016-06-09 Publication of CA2969456A1 publication Critical patent/CA2969456A1/en

Status Pending legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 319
239000000203 mixture Substances 0.000 title claims abstract description 143
238000011467 adoptive cell therapy Methods 0.000 title abstract description 22
108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 689
102000005962 receptors Human genes 0.000 claims abstract description 387
108020003175 receptors Proteins 0.000 claims abstract description 387
239000000427 antigen Substances 0.000 claims abstract description 211
108091007433 antigens Proteins 0.000 claims abstract description 211
102000036639 antigens Human genes 0.000 claims abstract description 211
230000028993 immune response Effects 0.000 claims abstract description 119
230000004048 modification Effects 0.000 claims abstract description 46
238000012986 modification Methods 0.000 claims abstract description 46
238000004519 manufacturing process Methods 0.000 claims abstract description 15
210000004027 cell Anatomy 0.000 claims description 867
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 218
201000010099 disease Diseases 0.000 claims description 206
150000001413 amino acids Chemical class 0.000 claims description 141
230000027455 binding Effects 0.000 claims description 138
108700010039 chimeric receptor Proteins 0.000 claims description 117
230000011664 signaling Effects 0.000 claims description 110
210000001744 T-lymphocyte Anatomy 0.000 claims description 90
206010028980 Neoplasm Diseases 0.000 claims description 81
230000000139 costimulatory effect Effects 0.000 claims description 81
125000003275 alpha amino acid group Chemical group 0.000 claims description 75
108090000765 processed proteins & peptides Proteins 0.000 claims description 64
241000282414 Homo sapiens Species 0.000 claims description 52
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 50
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 50
210000004369 blood Anatomy 0.000 claims description 48
239000008280 blood Substances 0.000 claims description 48
230000004068 intracellular signaling Effects 0.000 claims description 47
239000003550 marker Substances 0.000 claims description 47
210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 44
238000011282 treatment Methods 0.000 claims description 44
101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 35
102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 35
102000004196 processed proteins & peptides Human genes 0.000 claims description 34
210000003719 b-lymphocyte Anatomy 0.000 claims description 28
230000028996 humoral immune response Effects 0.000 claims description 28
241000894007 species Species 0.000 claims description 28
230000001086 cytosolic effect Effects 0.000 claims description 27
230000002829 reductive effect Effects 0.000 claims description 27
210000000265 leukocyte Anatomy 0.000 claims description 26
230000021633 leukocyte mediated immunity Effects 0.000 claims description 26
102000007079 Peptide Fragments Human genes 0.000 claims description 25
108010033276 Peptide Fragments Proteins 0.000 claims description 25
238000001514 detection method Methods 0.000 claims description 25
230000000694 effects Effects 0.000 claims description 25
230000014509 gene expression Effects 0.000 claims description 25
230000003213 activating effect Effects 0.000 claims description 24
230000009467 reduction Effects 0.000 claims description 24
230000003834 intracellular effect Effects 0.000 claims description 23
102000003839 Human Proteins Human genes 0.000 claims description 22
108090000144 Human Proteins Proteins 0.000 claims description 22
102100038080 B-cell receptor CD22 Human genes 0.000 claims description 21
102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 21
101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 21
101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 21
201000011510 cancer Diseases 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 21
238000001727 in vivo Methods 0.000 claims description 17
230000000977 initiatory effect Effects 0.000 claims description 17
210000002966 serum Anatomy 0.000 claims description 17
238000010361 transduction Methods 0.000 claims description 16
230000026683 transduction Effects 0.000 claims description 16
230000036210 malignancy Effects 0.000 claims description 15
229920001184 polypeptide Polymers 0.000 claims description 15
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 14
102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 14
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 14
210000004899 c-terminal region Anatomy 0.000 claims description 8
108020001756 ligand binding domains Proteins 0.000 claims description 8
-1 e.g. Proteins 0.000 abstract description 83
230000003828 downregulation Effects 0.000 abstract description 14
230000009261 transgenic effect Effects 0.000 abstract description 13
230000001976 improved effect Effects 0.000 abstract description 9
230000008901 benefit Effects 0.000 abstract description 4
235000001014 amino acid Nutrition 0.000 description 129
229940024606 amino acid Drugs 0.000 description 127
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 34
108091008874 T cell receptors Proteins 0.000 description 33
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 29
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 29
125000006850 spacer group Chemical group 0.000 description 29
238000000926 separation method Methods 0.000 description 28
150000007523 nucleic acids Chemical class 0.000 description 27
108020004707 nucleic acids Proteins 0.000 description 26
102000039446 nucleic acids Human genes 0.000 description 26
230000000875 corresponding effect Effects 0.000 description 25
238000002347 injection Methods 0.000 description 25
239000007924 injection Substances 0.000 description 25
230000004083 survival effect Effects 0.000 description 25
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 24
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 24
108700018351 Major Histocompatibility Complex Proteins 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 24
230000004044 response Effects 0.000 description 23
125000000539 amino acid group Chemical group 0.000 description 22
206010052015 cytokine release syndrome Diseases 0.000 description 21
238000001802 infusion Methods 0.000 description 21
210000001519 tissue Anatomy 0.000 description 21
238000003556 assay Methods 0.000 description 20
230000002163 immunogen Effects 0.000 description 20
239000000523 sample Substances 0.000 description 20
231100000331 toxic Toxicity 0.000 description 19
230000002588 toxic effect Effects 0.000 description 19
108700028369 Alleles Proteins 0.000 description 18
238000002659 cell therapy Methods 0.000 description 18
238000003780 insertion Methods 0.000 description 18
230000037431 insertion Effects 0.000 description 18
208000024891 symptom Diseases 0.000 description 18
230000001225 therapeutic effect Effects 0.000 description 18
102000006306 Antigen Receptors Human genes 0.000 description 17
108010083359 Antigen Receptors Proteins 0.000 description 17
230000002688 persistence Effects 0.000 description 17
230000008685 targeting Effects 0.000 description 17
239000013598 vector Substances 0.000 description 17
230000004913 activation Effects 0.000 description 16
230000006870 function Effects 0.000 description 16
230000001965 increasing effect Effects 0.000 description 16
239000002245 particle Substances 0.000 description 16
230000037396 body weight Effects 0.000 description 15
238000000684 flow cytometry Methods 0.000 description 15
230000004936 stimulating effect Effects 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
210000000056 organ Anatomy 0.000 description 14
239000008194 pharmaceutical composition Substances 0.000 description 14
108020004414 DNA Proteins 0.000 description 13
101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 13
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 13
238000009472 formulation Methods 0.000 description 13
230000005745 host immune response Effects 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
229940124597 therapeutic agent Drugs 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 12
102000004127 Cytokines Human genes 0.000 description 12
206010027476 Metastases Diseases 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
238000002955 isolation Methods 0.000 description 12
230000001988 toxicity Effects 0.000 description 12
231100000419 toxicity Toxicity 0.000 description 12
239000012636 effector Substances 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000000717 retained effect Effects 0.000 description 11
108010021625 Immunoglobulin Fragments Proteins 0.000 description 10
102000008394 Immunoglobulin Fragments Human genes 0.000 description 10
206010029350 Neurotoxicity Diseases 0.000 description 10
206010044221 Toxic encephalopathy Diseases 0.000 description 10
230000002209 hydrophobic effect Effects 0.000 description 10
238000011534 incubation Methods 0.000 description 10
231100000228 neurotoxicity Toxicity 0.000 description 10
230000007135 neurotoxicity Effects 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
239000000243 solution Substances 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 10
101001018097 Homo sapiens L-selectin Proteins 0.000 description 9
102100033467 L-selectin Human genes 0.000 description 9
239000011324 bead Substances 0.000 description 9
239000000872 buffer Substances 0.000 description 9
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 9
230000001177 retroviral effect Effects 0.000 description 9
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
102000043129 MHC class I family Human genes 0.000 description 8
108091054437 MHC class I family Proteins 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
238000011161 development Methods 0.000 description 8
230000018109 developmental process Effects 0.000 description 8
238000010353 genetic engineering Methods 0.000 description 8
230000001404 mediated effect Effects 0.000 description 8
239000003755 preservative agent Substances 0.000 description 8
238000012545 processing Methods 0.000 description 8
102220292761 rs576215366 Human genes 0.000 description 8
238000012546 transfer Methods 0.000 description 8
238000005406 washing Methods 0.000 description 8
239000012530 fluid Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
239000006249 magnetic particle Substances 0.000 description 7
239000000463 material Substances 0.000 description 7
238000003753 real-time PCR Methods 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
102000043131 MHC class II family Human genes 0.000 description 6
108091054438 MHC class II family Proteins 0.000 description 6
230000003044 adaptive effect Effects 0.000 description 6
108091008034 costimulatory receptors Proteins 0.000 description 6
229940079593 drug Drugs 0.000 description 6
210000002443 helper t lymphocyte Anatomy 0.000 description 6
210000000987 immune system Anatomy 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000003446 ligand Substances 0.000 description 6
230000005291 magnetic effect Effects 0.000 description 6
238000002826 magnetic-activated cell sorting Methods 0.000 description 6
230000009401 metastasis Effects 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
230000035772 mutation Effects 0.000 description 6
238000010186 staining Methods 0.000 description 6
208000023275 Autoimmune disease Diseases 0.000 description 5
108010074032 HLA-A2 Antigen Proteins 0.000 description 5
102000025850 HLA-A2 Antigen Human genes 0.000 description 5
101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 5
102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 5
241001529936 Murinae Species 0.000 description 5
241000700605 Viruses Species 0.000 description 5
238000002617 apheresis Methods 0.000 description 5
210000001124 body fluid Anatomy 0.000 description 5
230000007423 decrease Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
239000012634 fragment Substances 0.000 description 5
238000009169 immunotherapy Methods 0.000 description 5
230000007774 longterm Effects 0.000 description 5
210000003071 memory t lymphocyte Anatomy 0.000 description 5
239000011886 peripheral blood Substances 0.000 description 5
210000005259 peripheral blood Anatomy 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
230000000069 prophylactic effect Effects 0.000 description 5
210000000130 stem cell Anatomy 0.000 description 5
102220610001 Bestrophin-2_L34A_mutation Human genes 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 4
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 4
108010002350 Interleukin-2 Proteins 0.000 description 4
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
230000000735 allogeneic effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
210000001185 bone marrow Anatomy 0.000 description 4
239000006172 buffering agent Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
230000008859 change Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
229940127089 cytotoxic agent Drugs 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
239000003937 drug carrier Substances 0.000 description 4
210000003743 erythrocyte Anatomy 0.000 description 4
238000001415 gene therapy Methods 0.000 description 4
230000003308 immunostimulating effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000007726 management method Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 4
210000001616 monocyte Anatomy 0.000 description 4
230000003472 neutralizing effect Effects 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000009870 specific binding Effects 0.000 description 4
238000003860 storage Methods 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 4
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000011786 HLA-A Antigens Human genes 0.000 description 3
108010075704 HLA-A Antigens Proteins 0.000 description 3
208000032672 Histiocytosis haematophagic Diseases 0.000 description 3
101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 3
102000008100 Human Serum Albumin Human genes 0.000 description 3
108091006905 Human Serum Albumin Proteins 0.000 description 3
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
208000004987 Macrophage activation syndrome Diseases 0.000 description 3
108010052285 Membrane Proteins Proteins 0.000 description 3
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
108010090804 Streptavidin Proteins 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
206010045170 Tumour lysis syndrome Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
235000009582 asparagine Nutrition 0.000 description 3
229960001230 asparagine Drugs 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
238000000423 cell based assay Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000005138 cryopreservation Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
230000003013 cytotoxicity Effects 0.000 description 3
231100000135 cytotoxicity Toxicity 0.000 description 3
230000008030 elimination Effects 0.000 description 3
238000003379 elimination reaction Methods 0.000 description 3
238000007710 freezing Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
210000003714 granulocyte Anatomy 0.000 description 3
230000012010 growth Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000002865 immune cell Anatomy 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
230000004807 localization Effects 0.000 description 3
238000007885 magnetic separation Methods 0.000 description 3
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
230000002265 prevention Effects 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
238000011268 retreatment Methods 0.000 description 3
230000028327 secretion Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
238000001890 transfection Methods 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
208000010380 tumor lysis syndrome Diseases 0.000 description 3
241001430294 unidentified retrovirus Species 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
LZOIGVDSAMDBIO-LXWJMTKESA-N (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 LZOIGVDSAMDBIO-LXWJMTKESA-N 0.000 description 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000037914 B-cell disorder Diseases 0.000 description 2
102220610000 Bestrophin-2_R31A_mutation Human genes 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
108050006400 Cyclin Proteins 0.000 description 2
102000016736 Cyclin Human genes 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000002250 Hematologic Neoplasms Diseases 0.000 description 2
102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 2
102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 2
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 2
101100166600 Homo sapiens CD28 gene Proteins 0.000 description 2
101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 2
101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 2
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 2
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
102100031586 Leukocyte antigen CD37 Human genes 0.000 description 2
206010025323 Lymphomas Diseases 0.000 description 2
108010066345 MHC binding peptide Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
102000003735 Mesothelin Human genes 0.000 description 2
108090000015 Mesothelin Proteins 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
241000713883 Myeloproliferative sarcoma virus Species 0.000 description 2
102000016979 Other receptors Human genes 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
102400000745 Potential peptide Human genes 0.000 description 2
101800001357 Potential peptide Proteins 0.000 description 2
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
208000007660 Residual Neoplasm Diseases 0.000 description 2
241000713880 Spleen focus-forming virus Species 0.000 description 2
230000006044 T cell activation Effects 0.000 description 2
102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 2
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
208000008383 Wilms tumor Diseases 0.000 description 2
208000026448 Wilms tumor 1 Diseases 0.000 description 2
102100022748 Wilms tumor protein Human genes 0.000 description 2
101710127857 Wilms tumor protein Proteins 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000033289 adaptive immune response Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
238000013459 approach Methods 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
230000006037 cell lysis Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
229910052804 chromium Inorganic materials 0.000 description 2
239000011651 chromium Substances 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000000205 computational method Methods 0.000 description 2
238000009295 crossflow filtration Methods 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000007402 cytotoxic response Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
210000003162 effector t lymphocyte Anatomy 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
230000002998 immunogenetic effect Effects 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000000126 in silico method Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000036512 infertility Effects 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
238000012804 iterative process Methods 0.000 description 2
238000002372 labelling Methods 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
210000003563 lymphoid tissue Anatomy 0.000 description 2
RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000013507 mapping Methods 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000000066 myeloid cell Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
239000005022 packaging material Substances 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000005298 paramagnetic effect Effects 0.000 description 2
244000052769 pathogen Species 0.000 description 2
AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
230000002572 peristaltic effect Effects 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000004393 prognosis Methods 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
210000003705 ribosome Anatomy 0.000 description 2
235000004400 serine Nutrition 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000010257 thawing Methods 0.000 description 2
238000012384 transportation and delivery Methods 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
239000004474 valine Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
241000271566 Aves Species 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
208000003950 B-cell lymphoma Diseases 0.000 description 1
108700003860 Bacterial Genes Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
102100027314 Beta-2-microglobulin Human genes 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100027207 CD27 antigen Human genes 0.000 description 1
102100032912 CD44 antigen Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000000311 Cytosine Deaminase Human genes 0.000 description 1
108010080611 Cytosine Deaminase Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
206010012239 Delusion Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
238000011510 Elispot assay Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102100031940 Epithelial cell adhesion molecule Human genes 0.000 description 1
102100038595 Estrogen receptor Human genes 0.000 description 1
208000006168 Ewing Sarcoma Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000001398 Granzyme Human genes 0.000 description 1
108060005986 Granzyme Proteins 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
208000015023 Graves' disease Diseases 0.000 description 1
102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
102100040485 HLA class II histocompatibility antigen, DRB1 beta chain Human genes 0.000 description 1
102210042925 HLA-A*02:01 Human genes 0.000 description 1
102210024049 HLA-A*03:01 Human genes 0.000 description 1
102220404671 HLA-A*11:01 Human genes 0.000 description 1
108010026122 HLA-A*33 antigen Proteins 0.000 description 1
108010035452 HLA-A1 Antigen Proteins 0.000 description 1
108010013476 HLA-A24 Antigen Proteins 0.000 description 1
108010029526 HLA-A28 antigen Proteins 0.000 description 1
108010086377 HLA-A3 Antigen Proteins 0.000 description 1
108010018475 HLA-A31 antigen Proteins 0.000 description 1
102210024050 HLA-B*08:01 Human genes 0.000 description 1
108010028938 HLA-B45 antigen Proteins 0.000 description 1
108010091938 HLA-B7 Antigen Proteins 0.000 description 1
108010037618 HLA-C*08 antigen Proteins 0.000 description 1
108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
102210010948 HLA-DQB1*0201 Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010039343 HLA-DRB1 Chains Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 1
101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 description 1
101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 description 1
101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 1
101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 1
241000829111 Human polyomavirus 1 Species 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000037982 Immune checkpoint proteins Human genes 0.000 description 1
108091008036 Immune checkpoint proteins Proteins 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 1
101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 description 1
102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
206010027406 Mesothelioma Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102100034256 Mucin-1 Human genes 0.000 description 1
102100023123 Mucin-16 Human genes 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
102100036735 Prostate stem cell antigen Human genes 0.000 description 1
108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
102100038358 Prostate-specific antigen Human genes 0.000 description 1
102220471762 Proteasome subunit alpha type-7_K28A_mutation Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
201000001880 Sexual dysfunction Diseases 0.000 description 1
102100038081 Signal transducer CD24 Human genes 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
101800001271 Surface protein Proteins 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
108090000925 TNF receptor-associated factor 2 Proteins 0.000 description 1
102000004399 TNF receptor-associated factor 3 Human genes 0.000 description 1
108090000922 TNF receptor-associated factor 3 Proteins 0.000 description 1
102100034779 TRAF family member-associated NF-kappa-B activator Human genes 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
102100033725 Tumor necrosis factor receptor superfamily member 16 Human genes 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
239000002269 analeptic agent Substances 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000003432 anti-folate effect Effects 0.000 description 1
238000011861 anti-inflammatory therapy Methods 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
229940127074 antifolate Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000010928 autoimmune thyroid disease Diseases 0.000 description 1
231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
231100000871 behavioral problem Toxicity 0.000 description 1
229960001950 benzethonium chloride Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
108010081355 beta 2-Microglobulin Proteins 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000003320 cell separation method Methods 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000000975 co-precipitation Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
231100000876 cognitive deterioration Toxicity 0.000 description 1
208000010877 cognitive disease Diseases 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
231100000870 cognitive problem Toxicity 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
231100000867 compulsive behavior Toxicity 0.000 description 1
238000004590 computer program Methods 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
238000012258 culturing Methods 0.000 description 1
HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000007822 cytometric assay Methods 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
238000002784 cytotoxicity assay Methods 0.000 description 1
231100000263 cytotoxicity test Toxicity 0.000 description 1
229960000975 daunorubicin Drugs 0.000 description 1
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
231100000868 delusion Toxicity 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000013461 design Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000001671 embryonic stem cell Anatomy 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
108010038795 estrogen receptors Proteins 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
239000004052 folic acid antagonist Substances 0.000 description 1
230000003325 follicular Effects 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012595 freezing medium Substances 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
238000002169 hydrotherapy Methods 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
210000002861 immature t-cell Anatomy 0.000 description 1
229940126546 immune checkpoint molecule Drugs 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
230000017555 immunoglobulin mediated immune response Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
230000015788 innate immune response Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000031146 intracellular signal transduction Effects 0.000 description 1
238000010212 intracellular staining Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000002523 lectin Substances 0.000 description 1
125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
231100000861 limb weakness Toxicity 0.000 description 1
208000027905 limb weakness Diseases 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
231100000875 loss of motor control Toxicity 0.000 description 1
231100000864 loss of vision Toxicity 0.000 description 1
208000018769 loss of vision Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
210000005210 lymphoid organ Anatomy 0.000 description 1
230000001589 lymphoproliferative effect Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
230000002934 lysing effect Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Chemical class 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000009126 molecular therapy Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000002894 multi-fate stem cell Anatomy 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000010807 negative regulation of binding Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000862 numbness Toxicity 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000009437 off-target effect Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000002203 pretreatment Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
102000003998 progesterone receptors Human genes 0.000 description 1
108090000468 progesterone receptors Proteins 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000001902 propagating effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004043 responsiveness Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
102200112956 rs104893657 Human genes 0.000 description 1
102200031779 rs3204853 Human genes 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
231100000872 sexual dysfunction Toxicity 0.000 description 1
230000009450 sialylation Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
239000004299 sodium benzoate Substances 0.000 description 1
235000010234 sodium benzoate Nutrition 0.000 description 1
229960003885 sodium benzoate Drugs 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
206010042863 synovial sarcoma Diseases 0.000 description 1
238000012385 systemic delivery Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
101150047061 tag-72 gene Proteins 0.000 description 1
238000002626 targeted therapy Methods 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
229960003989 tocilizumab Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000035160 transmembrane proteins Human genes 0.000 description 1
108091005703 transmembrane proteins Proteins 0.000 description 1
230000017105 transposition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
239000010937 tungsten Substances 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000012808 vapor phase Substances 0.000 description 1
230000035899 viability Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Biotechnology (AREA)
Hematology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA2969456A 2014-12-03 2015-12-03 Methods and compositions for adoptive cell therapy Pending CA2969456A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462087224P	2014-12-03	2014-12-03
US62/087,224		2014-12-03
PCT/US2015/063839 WO2016090190A1 (en)	2014-12-03	2015-12-03	Methods and compositions for adoptive cell therapy

Publications (1)

Publication Number	Publication Date
CA2969456A1 true CA2969456A1 (en)	2016-06-09

Family

ID=55022703

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2969456A Pending CA2969456A1 (en)	2014-12-03	2015-12-03	Methods and compositions for adoptive cell therapy

Country Status (11)

Country	Link
US (3)	US11266739B2 (de)
EP (2)	EP3766895B1 (de)
JP (2)	JP7068820B2 (de)
KR (1)	KR20170087514A (de)
CN (1)	CN107206025A (de)
AU (3)	AU2015358400B2 (de)
CA (1)	CA2969456A1 (de)
ES (1)	ES2819553T3 (de)
HK (1)	HK1244826A1 (de)
MX (2)	MX2017007138A (de)
WO (1)	WO2016090190A1 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101605421B1 (ko)	2014-03-05	2016-03-23	국립암센터	B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
US10507219B2 (en)	2014-10-20	2019-12-17	Juno Therapeutics, Inc.	Methods and compositions for dosing in adoptive cell therapy
US11253546B2 (en)	2014-12-15	2022-02-22	The Regents Of The University Of California	Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
CN114634943A (zh)	2015-05-18	2022-06-17	T细胞受体治疗公司	使用融合蛋白对tcr重编程的组合物和方法
JP7195141B2 (ja)	2015-10-22	2022-12-23	ジュノセラピューティクスゲーエムベーハー	形質導入のための方法、キット、作用物質および装置
US20180355014A1 (en) *	2015-12-03	2018-12-13	Juno Therapeutics, Inc.	Modified chimeric receptors and related compositions and methods
US20180135011A1 (en) *	2017-03-13	2018-05-17	Berkeley Lights, Inc.	Selection and cloning of t lymphocytes in a microfluidic device
CN109715668A (zh)	2016-08-02	2019-05-03	T细胞受体治疗公司	用于使用融合蛋白进行tcr重编程的组合物和方法
JP6994021B2 (ja) *	2016-08-26	2022-01-14	ジュノーセラピューティクスインコーポレイテッド	細胞組成物中に存在する粒子を計数する方法
JP2019529565A (ja)	2016-09-28	2019-10-17	アトッサ・ジェネティックス・インコーポレイテッド	養子細胞治療の方法
AU2017338846B2 (en) *	2016-10-04	2020-09-24	Precision Biosciences, Inc.	Co-stimulatory domains for use in genetically-modified cells
PL3445787T3 (pl)	2016-10-07	2021-05-31	TCR2 Therapeutics Inc.	Kompozycje i sposoby reprogramowania receptorów limfocytów t przy użyciu białek fuzyjnych
AU2017363311A1 (en)	2016-11-22	2019-06-13	TCR2 Therapeutics Inc.	Compositions and methods for TCR reprogramming using fusion proteins
WO2018102761A1 (en) *	2016-12-02	2018-06-07	City Of Hope	Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors
KR20190098747A (ko) *	2016-12-05	2019-08-22	주노 쎄러퓨티크스 인코퍼레이티드	입양 세포 치료법을 위한 조작된 세포의 제조방법
CN108395482B (zh)	2017-02-08	2021-02-05	西比曼生物科技（香港）有限公司	一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
WO2018154386A1 (en) *	2017-02-21	2018-08-30	Eutilex Co., Ltd.	Hla-dr car-t compositions and methods of making and using the same
BR112019019005A2 (pt)	2017-03-14	2020-04-14	Sara Elizabeth Church	métodos para armazenagem criogênica
JOP20180040A1 (ar)	2017-04-20	2019-01-30	Gilead Sciences Inc	مثبطات pd-1/pd-l1
CA3061546C (en) *	2017-04-28	2023-09-19	Julius-Maximilians-Universitat Wurzburg	Ror1-specific chimeric antigen receptors (car) with humanized targeting domains
CN110740734A (zh)	2017-06-07	2020-01-31	西雅图基因公司	具有降低的表面岩藻糖基化的t细胞及其制备和使用方法
IL306102A (en)	2017-06-07	2023-11-01	Precigen Inc	Expression of new cell markers
EP3644721A1 (de) *	2017-06-29	2020-05-06	Juno Therapeutics, Inc.	Mausmodell zur auswertung von toxizitäten im zusammenhang mit immunotherapien
JP2021505168A (ja) *	2017-12-08	2021-02-18	ジュノーセラピューティクスインコーポレイテッド	操作されたｔ細胞の組成物を製造するための方法
CA3084569A1 (en)	2017-12-20	2019-06-27	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh)	2017-12-20	2023-09-12	捷克共和国有机化学与生物化学研究所	活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
CN109988242A (zh) *	2018-01-02	2019-07-09	武汉波睿达生物科技有限公司	联合嵌合抗原受体、表达载体、慢病毒及t细胞
MY196582A (en)	2018-02-13	2023-04-19	Gilead Sciences Inc	PD-1/PD-L1 Inhibitors
TWI818007B (zh)	2018-04-06	2023-10-11	捷克科學院有機化學與生物化學研究所	2'3'-環二核苷酸
TWI833744B (zh)	2018-04-06	2024-03-01	捷克科學院有機化學與生物化學研究所	3'3'-環二核苷酸
TW202005654A (zh)	2018-04-06	2020-02-01	捷克科學院有機化學與生物化學研究所	２，２，─環二核苷酸
CA3093130C (en)	2018-04-19	2023-10-17	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
TW202014193A (zh)	2018-05-03	2020-04-16	捷克科學院有機化學與生物化學研究所	包含碳環核苷酸之2’3’－環二核苷酸
CN112118845B (zh)	2018-05-14	2023-06-13	吉利德科学公司	Mcl-1抑制剂
ES2962674T3 (es)	2018-07-13	2024-03-20	Gilead Sciences Inc	Inhibidores PD-1/PD-L1
CA3109209A1 (en)	2018-08-10	2020-02-13	Eutilex Co., Ltd.	Chimeric antigen receptor that binds hla-dr and car-t cell
US20220348682A1 (en)	2018-08-30	2022-11-03	Innovative Cellular Therapeutics Holdings, Ltd.	Chimeric antigen receptor cells for treating solid tumor
US11179397B2 (en)	2018-10-03	2021-11-23	Gilead Sciences, Inc.	Imidazopyrimidine derivatives
WO2020086556A1 (en)	2018-10-24	2020-04-30	Gilead Sciences, Inc.	Pd-1/pd-l1 inhibitors
TW202136261A (zh)	2018-10-31	2021-10-01	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
TW202136260A (zh)	2018-10-31	2021-10-01	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
AU2020231201A1 (en)	2019-03-07	2021-08-26	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	2'3'-cyclic dinucleotides and prodrugs thereof
US20220143061A1 (en)	2019-03-07	2022-05-12	Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I.	3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (de)	2019-03-07	2022-01-12	Institute of Organic Chemistry and Biochemistry ASCR, V.V.I.	3'3'-cyclisches dinukleotid-analogon mit einem cyclopentanyl-modifizierten nukleotid als sting-modulator
TW202212339A (zh)	2019-04-17	2022-04-01	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
TW202210480A (zh)	2019-04-17	2022-03-16	美商基利科學股份有限公司	類鐸受體調節劑之固體形式
US11453681B2 (en)	2019-05-23	2022-09-27	Gilead Sciences, Inc.	Substituted eneoxindoles and uses thereof
CN114245807A (zh)	2019-06-25	2022-03-25	吉利德科学公司	Flt3l-fc融合蛋白和使用方法
CA3208912A1 (en)	2019-10-18	2021-04-22	Forty Seven, Inc.	Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
MX2022005123A (es)	2019-10-31	2022-05-30	Forty Seven Inc	Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico.
TWI778443B (zh)	2019-11-12	2022-09-21	美商基利科學股份有限公司	Mcl1抑制劑
PE20230376A1 (es)	2019-12-24	2023-03-06	Carna Biosciences Inc	Compuestos moduladores de la diacilglicerol quinasa
JP7439279B2 (ja) *	2020-02-13	2024-02-27	イミュノファームテクノロジーカンパニーリミテッド	キメラ抗原受容体の最適化
MX2022013619A (es)	2020-05-01	2022-11-16	Gilead Sciences Inc	Compuestos de 2,4-dioxopirimidina que inhiben cd73.
US12043654B2 (en)	2020-06-02	2024-07-23	Innovative Cellular Therapeutics Holdings, Ltd.	Anti-GCC antibody and CAR thereof for treating digestive system cancer
TW202302145A (zh)	2021-04-14	2023-01-16	美商基利科學股份有限公司	ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
US20220389394A1 (en)	2021-05-18	2022-12-08	Gilead Sciences, Inc.	METHODS OF USING FLT3L-Fc FUSION PROTEINS
EP4359413A1 (de)	2021-06-23	2024-05-01	Gilead Sciences, Inc.	Diacylglyercolkinase modulierende verbindungen
JP2024520593A (ja)	2021-06-23	2024-05-24	ギリアードサイエンシーズ，インコーポレイテッド	ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物
WO2022271684A1 (en)	2021-06-23	2022-12-29	Gilead Sciences, Inc.	Diacylglyercol kinase modulating compounds
CN117377671A (zh)	2021-06-23	2024-01-09	吉利德科学公司	二酰基甘油激酶调节化合物
WO2023154890A2 (en) *	2022-02-11	2023-08-17	Fred Hutchinson Cancer Center	Chimeric antigen receptors binding steap1
US20230355796A1 (en)	2022-03-24	2023-11-09	Gilead Sciences, Inc.	Combination therapy for treating trop-2 expressing cancers
TW202345901A (zh)	2022-04-05	2023-12-01	美商基利科學股份有限公司	用於治療結腸直腸癌之組合療法
US20240091351A1 (en)	2022-09-21	2024-03-21	Gilead Sciences, Inc.	FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4452773A (en)	1982-04-05	1984-06-05	Canadian Patents And Development Limited	Magnetic iron-dextran microspheres
US4690915A (en)	1985-08-08	1987-09-01	The United States Of America As Represented By The Department Of Health And Human Services	Adoptive immunotherapy as a treatment modality in humans
US4795698A (en)	1985-10-04	1989-01-03	Immunicon Corporation	Magnetic-polymer particles
IN165717B (de)	1986-08-07	1989-12-23	Battelle Memorial Institute
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es)	1988-12-28	1995-03-16	Stefan Miltenyi	Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en)	1990-09-26	1993-04-06	Immunicon Corporation	Apparatus and methods for magnetic separation
IE913929A1 (en)	1990-11-13	1992-05-20	Immunex Corp	Bifunctional selectable fusion genes
CA2163427A1 (en)	1993-05-21	1994-12-08	Stephen D. Lupton	Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5827642A (en)	1994-08-31	1998-10-27	Fred Hutchinson Cancer Research Center	Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de)	1996-03-06	1997-06-26	Medigene Gmbh	Transduktionssystem und seine Verwendung
WO1997034634A1 (en)	1996-03-20	1997-09-25	Sloan-Kettering Institute For Cancer Research	Single chain fv constructs of anti-ganglioside gd2 antibodies
WO2000014257A1 (en)	1998-09-04	2000-03-16	Sloan-Kettering Institute For Cancer Research	Fusion receptors specific for prostate-specific membrane antigen and uses thereof
WO2000023573A2 (en)	1998-10-20	2000-04-27	City Of Hope	Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
CA2410510A1 (en)	2000-06-02	2001-12-13	Memorial Sloan-Kettering Cancer Center	Artificial antigen presenting cells and methods of use thereof
EP1334188B1 (de)	2000-11-07	2006-08-30	City of Hope	Cd19-spezifische umgezielte immunzellen
US7070995B2 (en)	2001-04-11	2006-07-04	City Of Hope	CE7-specific redirected immune cells
US20090257994A1 (en)	2001-04-30	2009-10-15	City Of Hope	Chimeric immunoreceptor useful in treating human cancers
EP1448584B1 (de)	2001-09-26	2010-05-19	The Government of the United States of America as represented by The Secretary of Health and Human Services	Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
US20030170238A1 (en)	2002-03-07	2003-09-11	Gruenberg Micheal L.	Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en)	2002-05-28	2008-11-04	Sloan-Kettering Institute For Cancer Research	Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en)	2003-03-11	2005-06-16	City Of Hope	Mammalian antigen-presenting T cells and bi-specific T cells
US7435596B2 (en)	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
DK2141997T3 (da)	2007-03-30	2013-02-11	Sloan Kettering Inst Cancer	Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
ES2374863T3 (es)	2007-12-07	2012-02-22	Miltenyi Biotec Gmbh	Centrífuga para separar una muestra en por lo menos dos componentes.
US8479118B2 (en)	2007-12-10	2013-07-02	Microsoft Corporation	Switching search providers within a browser search box
US8591889B2 (en)	2008-04-04	2013-11-26	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Human monoclonal antibodies specific for CD22
US20120164718A1 (en)	2008-05-06	2012-06-28	Innovative Micro Technology	Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja)	2008-05-27	2013-04-03	キヤノン株式会社	管理装置、画像形成装置及びそれらの処理方法
ES2899174T3 (es)	2008-08-26	2022-03-10	Hope City	Método y composiciones para el funcionamiento mejorado del efecto antitumoral de las células T
CA2753158A1 (en)	2009-02-23	2010-08-26	Glenmark Pharmaceuticals S.A.	Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (de) *	2009-06-24	2016-09-07	The Feinstein Institute for Medical Research	Verfahren zur behandlung chronischer lymphozytenleukämie
TR201904484T4 (tr)	2009-11-03	2019-05-21	Hope City	Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
JP5712516B2 (ja) *	2010-07-14	2015-05-07	住友電気工業株式会社	半導体装置
CN110452882A (zh) *	2010-12-09	2019-11-15	宾夕法尼亚大学董事会	嵌合抗原受体-修饰的t细胞治疗癌症的用途
CN110200997A (zh)	2011-03-23	2019-09-06	弗雷德哈钦森癌症研究中心	用于细胞免疫治疗的方法和组合物
US8398282B2 (en)	2011-05-12	2013-03-19	Delphi Technologies, Inc.	Vehicle front lighting assembly and systems having a variable tint electrowetting element
US9366138B2 (en) *	2011-07-28	2016-06-14	Pratt & Whitney Canada Corp.	Rotary internal combustion engine with phasing gear
EP2768863B1 (de)	2011-10-20	2017-09-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Chimäre anti-cd22-antigenrezeptoren
WO2013071154A1 (en)	2011-11-11	2013-05-16	Fred Hutchinson Cancer Research Center	Cyclin a1-targeted t-cell immunotherapy for cancer
AU2013221672B2 (en)	2012-02-13	2017-11-09	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en)	2012-02-22	2013-08-29	The Trustees Of The University Of Pennsylvania	Double transgenic t cells comprising a car and a tcr and their methods of use
RU2018130123A (ru)	2012-05-03	2018-11-07	Фред Хатчинсон Кансэр Рисёч Сентер	Клетка, экспрессирующая t-клеточный рецептор (tcr), для применения в клеточной иммунотерапии
KR20150029714A (ko)	2012-07-13	2015-03-18	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
EP3824905A1 (de)	2012-08-20	2021-05-26	Fred Hutchinson Cancer Research Center	Verfahren und zusammensetzungen für eine zell-immuntherapie
SG11201502598SA (en)	2012-10-02	2015-05-28	Sloan Kettering Inst Cancer	Compositions and methods for immunotherapy
RU2658485C2 (ru)	2012-10-24	2018-06-21	Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез	Химерные антигенные рецепторы м971
CN104781789B (zh)	2012-12-20	2018-06-05	三菱电机株式会社	车载装置
SG11201507688VA (en)	2013-03-15	2015-10-29	Sloan Kettering Inst Cancer	Compositions and methods for immunotherapy
TWI654206B (zh)	2013-03-16	2019-03-21	諾華公司	使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en)	2013-08-20	2015-08-18	Ricoh Company, Ltd.	Image forming apparatus
US10144770B2 (en)	2013-10-17	2018-12-04	National University Of Singapore	Chimeric receptors and uses thereof in immune therapy
EP3593812A3 (de)	2014-03-15	2020-05-27	Novartis AG	Behandlung von krebs mithilfe eines chimären antigenrezeptors
US20170015746A1 (en)	2014-04-10	2017-01-19	Seattle Children's Hospital (dba Seattle Children's Research Institute)	Defined composition gene modified t-cell products
SG11201700770PA (en)	2014-08-19	2017-03-30	Novartis Ag	Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
US10507219B2 (en)	2014-10-20	2019-12-17	Juno Therapeutics, Inc.	Methods and compositions for dosing in adoptive cell therapy
CN104910279B (zh)	2015-06-05	2019-02-22	重庆精准生物技术有限公司	靶向癌胚抗原的嵌合抗原受体、慢病毒表达载体及其制备方法和应用
US20180355014A1 (en)	2015-12-03	2018-12-13	Juno Therapeutics, Inc.	Modified chimeric receptors and related compositions and methods
ES2928167T3 (es)	2015-12-03	2022-11-15	Juno Therapeutics Inc	Composiciones y métodos para reducir las respuestas inmunitarias contra receptores de antígenos quiméricos

2015
- 2015-12-03 JP JP2017529321A patent/JP7068820B2/ja active Active
- 2015-12-03 CN CN201580075303.2A patent/CN107206025A/zh active Pending
- 2015-12-03 KR KR1020177018369A patent/KR20170087514A/ko not_active Application Discontinuation
- 2015-12-03 MX MX2017007138A patent/MX2017007138A/es unknown
- 2015-12-03 WO PCT/US2015/063839 patent/WO2016090190A1/en active Application Filing
- 2015-12-03 ES ES15816318T patent/ES2819553T3/es active Active
- 2015-12-03 EP EP20180622.1A patent/EP3766895B1/de active Active
- 2015-12-03 CA CA2969456A patent/CA2969456A1/en active Pending
- 2015-12-03 EP EP15816318.8A patent/EP3227323B1/de active Active
- 2015-12-03 US US14/958,919 patent/US11266739B2/en active Active
- 2015-12-03 AU AU2015358400A patent/AU2015358400B2/en active Active
2017
- 2017-06-05 MX MX2022005955A patent/MX2022005955A/es unknown
2018
- 2018-03-27 HK HK18104179.5A patent/HK1244826A1/zh unknown
2020
- 2020-12-04 AU AU2020281158A patent/AU2020281158B2/en active Active
2022
- 2022-01-28 US US17/588,149 patent/US20220280642A1/en active Pending
- 2022-04-20 JP JP2022069168A patent/JP2022101625A/ja active Pending
2023
- 2023-10-20 US US18/491,633 patent/US20240066122A1/en active Pending
2024
- 2024-04-07 AU AU2024202225A patent/AU2024202225A1/en active Pending

Also Published As

Publication number	Publication date
AU2015358400B2 (en)	2020-09-10
MX2022005955A (es)	2022-06-29
JP2022101625A (ja)	2022-07-06
EP3766895B1 (de)	2024-07-10
AU2020281158A1 (en)	2021-01-14
MX2017007138A (es)	2017-08-28
US20160158359A1 (en)	2016-06-09
ES2819553T3 (es)	2021-04-16
AU2015358400A1 (en)	2017-06-22
AU2024202225A1 (en)	2024-06-20
HK1244826A1 (zh)	2018-08-17
JP2017537919A (ja)	2017-12-21
KR20170087514A (ko)	2017-07-28
AU2020281158B2 (en)	2024-02-08
US20220280642A1 (en)	2022-09-08
EP3227323B1 (de)	2020-08-05
US11266739B2 (en)	2022-03-08
WO2016090190A1 (en)	2016-06-09
US20240066122A1 (en)	2024-02-29
EP3227323A1 (de)	2017-10-11
JP7068820B2 (ja)	2022-05-17
EP3766895A1 (de)	2021-01-20
CN107206025A (zh)	2017-09-26

Legal Events

Date	Code	Title	Description
2020-12-16	EEER	Examination request	Effective date: 20201201
2022-06-01	EEER	Examination request	Effective date: 20201201
2022-11-02	EEER	Examination request	Effective date: 20201201
2023-01-31	EEER	Examination request	Effective date: 20201201
2023-06-22	EEER	Examination request	Effective date: 20201201
2023-07-21	EEER	Examination request	Effective date: 20201201
2023-10-31	EEER	Examination request	Effective date: 20201201
2023-12-12	EEER	Examination request	Effective date: 20201201

Publication	Publication Date	Title
AU2020281158B2 (en)	2024-02-08	Methods and compositions for adoptive cell therapy
AU2016363025B2 (en)	2021-04-08	Modified chimeric receptors and related compositions and methods
US20210363258A1 (en)	2021-11-25	Hpv-specific binding molecules
EP3383419B1 (de)	2022-08-03	Zusammensetzungen und methoden zur reduktion der immunantwort gegen chimäre antigen rezeptoren
IL251774B (en)	2022-07-01	Methods and preparations for dosing in stress cell therapy
US20190099447A1 (en)	2019-04-04	Adoptive cell therapies as early treatment options